-
Mashup Score: 1Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation - 2 year(s) ago
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Primary central nervous system lymphoma - 2 year(s) ago
Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Primary central nervous system lymphoma https://t.co/uCUIrhumw7 #lymsm #PCNSL https://t.co/MU7vzYcn1F
-
-
Mashup Score: 2Primary central nervous system lymphoma - 2 year(s) ago
Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Primary central nervous system #lymphoma #PCNSL | @BloodJournal | American Society of Hematology @ASH_hematology #lymsm https://t.co/h76Brr2eXl
-
-
Mashup Score: 0
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combination orelabrutinib and sintilimab can produce rapid responses in patients with relapsed or refractory primary central nervous system #lymphoma, according to research presented at the @EHA_Hematology conference #EHA2022. https://t.co/b7opaUiVPW #PCNSL
-
-
Mashup Score: 0Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma - 2 year(s) ago
(2022). Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma. Hematology: Vol. 27, No. 1, pp. 105-112.
Source: Taylor & FrancisCategories: Hem/Oncs, Latest HeadlinesTweet-
Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma #lymsm #PCNSL https://t.co/ydcisaT3ic
-
-
Mashup Score: 1
219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C). A second randomization allocated patients with responsive/stable disease to whole-brain…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS #lymphoma: 7-year results of the IELSG32 randomized trial #lymsm #PCNSL #bmtsm https://t.co/D9J915xgDh
-
-
Mashup Score: 2
Purpose Primary Central Nervous System Lymphoma (PCNSL) is an aggressive tumor that is confined to the CNS. Although the provision of high-dose methotrexate (HD-MTX) has remarkably improved outcomes in PCNSL patients, the optimal treatment regimens and standard MTX dose for induction therapy have been largely controversial. Herein, we sought to explore the impact of adjuvant rituximab and…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A recent study highlights the shorter survival in elderly patients with #PCNSL which may be related to the relatively lower doses of HD-#MTX. @NeurosurgeryUab @abdeatkine @MoaazAbdelrash1 @Lymphoma_MD @MinaLobbous https://t.co/xFnSVKIblo https://t.co/urnnPgFDGF
-
-
Mashup Score: 2Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial - 2 year(s) ago
Relapsed/refractory primary central nervous system (CNS) lymphoma (PCNSL) has a terrible prognosis. Frigault et al reported encouraging results with CAR-T cell
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Hematology Safety and efficacy of #tisagenlecleucel in primary CNS #lymphoma #PCNSL: a phase 1/2 clinical trial | @BloodJournal | American Society of Hematology @ASH_hematology #lymsm #CARTcell https://t.co/7jETUt7YPk
-
-
Mashup Score: 2Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients - Journal of Neuro-Oncology - 2 year(s) ago
To avoid an unnecessary extend of surgery in primary central nervous system lymphoma (PCNSL), the diagnosis should be suspected after MRI.Pre-treatment MRI examinations of 100 immunologically competent patients with biopsy-proven PCNSL were evaluated. All patients had T2- and T1-weighted images with contrast enhancement. Diffusion-weighted MRI (DW-MRI) was available in 15, proton-MR-spectroscopy…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Characteristic imaging features of #PCNSL are contrast-enhancing lesions with a diameter of at least 15 mm in contact with the subarachnoid space. @uni_tue @UniofOxford #BTSM #JNO https://t.co/Cpsrl7ciWH https://t.co/ojImeRFGz5
-
-
Mashup Score: 0MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma - Journal of Neuro-Oncology - 2 year(s) ago
Introduction To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients. Methods In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed PCNSL were randomized between high-dose methotrexate-based chemotherapy with or without rituximab. Data on potential (MMSE-score),…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neurocognitive disturbances, measured with the #MMSE at baseline, are an unfavorable prognostic factor for both PFS and OS in adult #PCNSL patients up to 70 years-old. @jacolinebrom https://t.co/UPJiInrHLp https://t.co/ofG1KXFNUL
-
RT @EANOassociation: Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation. https://t.co/wvkdCvb4vT #btsm #pcnsl @JCO_ASCO